GLP-1s are making headlines and breast cancer researchers are paying close attention. A new CURE article featuring insights from Komen staff explores what we know so far, what questions remain and why any decision about GLP-1s should be guided by an oncology care team. https://bit.ly/4fFEJss

Hispanic and Latina women are often diagnosed with later-stage breast cancers than white women, possibly due to delays in follow-up care after an abnormal screening mammogram. It's important to know your risk factors and advocate for yourself. Visit komen.org to learn more.

Chemo brain isn’t random. It’s not “just in your head” -- Estrogen changes and treatment can affect how your brain communicates. Learn the biology behind brain fog in our latest Under the Microscope video. Watch the full episode: https://youtu.be/desV6bWFdyY

Cancer clinical trial enrollment by adults in the U.S. is less than 5%. Breast cancer clinical trials study prevention, new screening tests and treatment options, as well as quality of life issues. Learn more about clinical trials at komen.org or email [email protected].

We're proud to have supported investigators who contributed to Phase III clinical trials that led to the latest expanded FDA approval for the use of each drug. You can learn all about these clinical trial results through our Breast Cancer Breakthroughs Series: https://bit.ly/4amC5EZ

Many of today’s most significant advances in breast cancer treatment began as bold, early-stage concepts. We're proud to support innovative research that leverages AI, advanced technologies & new therapies to improve patient outcomes. Learn more about our 2026 Research Grants https://bit.ly/4wriexd

Through clinical trials, researchers are uncovering smarter therapies that help patients live longer, feel better and hold onto the ultimate hope: a future without breast cancer. Learn more about the top breast cancer clinical trials featured at @ascocancer.bsky.social: https://bit.ly/4oHaCDM

The cures are closer than ever. We’re pursuing the right data, the right questions and the treatments to make it possible. That's why today, we're excited to announce this year's $15.4 million investement in research and it's all thanks to your support!

Many men have been where you are today. Social support is important after a breast cancer diagnosis. The Komen Patient Care Center can help you find a support group for you and your loved ones, or resources in your area. Call 1-877-GO KOMEN or email [email protected]. We're here for you.

Tune in to our upcoming episode to learn what's new in imaging for MBC. Bring your questions ready - it's a live Q&A! Dr. David Mankoff will share updated imaging practices for ER+ MBC and new data from a national clinical trial on FDG PET/CT for bone metastases. Register: https://bit.ly/4vebmTo

Let’s talk about male breast cancer. Yes, it happens! Jake Messier is joined by Bret Miller and Richard Loud to talk about how they were initially diagnosed, their treatment plan, and resources that have helped them. Watch our premiere Men’s Health Month episode now: https://youtu.be/HgTyPTCT3HI

Men who get breast cancer are more likely to have an inherited gene mutation than women who get breast cancer. For this reason, genetic testing for BRCA1 a&BRCA2 (BRCA1/2) gene mutations is recommended for all men diagnosed w/ breast cancer. Learn more about genetic testing: https://bit.ly/4amgGvv

Thrilled to see many Komen-supported grantees & posters at #ASCO26. Each reflects scientific progress and the dedication of researchers improving outcomes for people impacted by breast cancer. Proud to support science, moving us closer to a world without breast cancer. @ascocancer.bsky.social

The future of breast cancer care depends on continued groundbreaking discoveries, and there’s incredible work happening right now.

🧬 Sara Hurvitz, MD presents VIKTORIA-1 at #ASCO26: In HR+/HER2- PIK3CA-mutant breast cancer after CDK4/6i, gedatolisib + fulvestrant (with or without palbociclib) doubled progression-free survival vs standard of care (11.1 vs 5.6 months). 🎯 @ascocancer.bsky.social#ASCO26

🧬 Francois Bidard, MD, Ph.D. presents SERENA-6 at #ASCO26: Switching to camizestrant + CDK4/6i when ESR1 mutations emerge during first-line therapy improved outcomes through 2 lines of treatment in HR+/HER2- advanced breast cancer @ascocancer.bsky.social#ASCO26

GLP-1 use is rising but what about #breastcancer risk? Long term safety matters. At #ASCO26, Elizabeth Susan McDonald, MD, PhD reported GLP-1 treatment was associated with lower BC incidence in women, but clinical trials are needed to confirm a true risk reduction effect. @ascocancer.bsky.social#breastcancer

PANKU-Breast02 phase 3 trial: iza-bren vs chemo in pre-treated metastatic TNBC. 📊 Jiong Wu, MD, PhD reported that patients had improved overall survival & stayed progression-free longer with manageable side effects, suggesting iza-bren could become a new standard option. @ascocancer.bsky.social

Can ADCs improve outcomes in pts who can't get immunotherapy? 🤔 At #ASCO26, David Cescon, MD, PhD shared new TROPION-Breast02 data: Dato-DXd helped pts go longer w/o progression & delayed need for further tx vs chemo, supporting it as a potential new 1L standard in mTNBC. @ascocancer.bsky.social

🧬Dr. Kevin Kalinsky presents ASCENT-04 at #ASCO26: Starting on sacituzumab govitecan + pembro upfront led to better outcomes through 2 lines of treatment in PD-L1+ metastatic TNBC - even vs patients who eventually received SG later. @ascocancer.bsky.social#ASCO26

ASCENT-03 tests sacituzumab govitecan (SG) vs chemo in 1L metastatic TNBC Dr. Sara Tolaney presented new data showing improved PFS after next line of treatment & subsequent therapies, supporting SG as a potential new standard of care for those not eligible for PD-L1 therapy. @ascocancer.bsky.social

At #ASCO26, Komen grantee Sharon Giordano, the recipient of the Gianni Bonadonna Breast Cancer Award, shared insights on opportunities, challenges and lessons learned in breast cancer outcomes research 🏆 @ascocancer.bsky.social#ASCO26

Phase 3 KEYNOTE-522 final results 👀💥 Javier Cortes, MD, PhD presents data from the trial evaluating pembrolizumab + chemo before surgery, followed by adjuvant pembrolizumab vs placebo. #ASCO26 @ascocancer.bsky.social#ASCO26

Recurrence remains a challenge in HR+/HER2- early #breastcancer. Phase 3 lidERA trial previously showed improvement with giredestrant (oral SERD) vs standard hormone therapy 📈 Peter Schmid, MD, PhD presents results by menopausal status at #ASCO26 @ascocancer.bsky.social#breastcancer

New biomarker insights from NATALEE trial presented by Stephen Chia, MD 📊 Baseline gene expression shows prognostic & predictive impact in HR+/HER2- early #breastcancer treated with adjuvant ribociclib + aromatase inhibitor #ASCO26 @ascocancer.bsky.social#breastcancer

Can some people safely avoid chemo in higher-risk early breast cancer? 🤔 OPTIMA phase 3 tests a genomic-guided strategy vs standard of care in HR+/HER2- #breastcancer. Robert Stein, PhD presents first results at #ASCO26 @ascocancer.bsky.social#breastcancer

Congratulations to past and present Komen grantees Nancy Davidson MD, Sharon Giordano MD, Charles Loprinzi MD and Jason Freeman for receiving awards at this year's #ASCO2026 !!!🎉 @ascocancer.bsky.social#ASCO2026

📢 Heading to #ASCO26? Visit us at booth 13000 in the Exhibit Hall 📆 May 30-June 1 from 9 am - 5 pm Connect with our team and learn more about our work in patient support, advocacy, research funding, education and resources for the breast cancer community. @ascocancer.bsky.social#ASCO26

"Organizations like Susan G. Komen continue to highlight the importance of collaboration between healthcare providers, policymakers, community leaders, and advocacy groups to ensure lifesaving services remain available and accessible to all."

Breast cancer surgery can come with lots of uncertainty and questions, especially when it comes to healing, recovery and dealing with things like scar tissue, swelling and surgical drains.

New FDA approval: Trastuzumab deruxtecan (Enhertu) is now approved in the U.S. for HER2+ early breast cancer in both neoadjuvant (before surgery) and adjuvant (post-surgery) settings, based on DESTINY-Breast05 and DESTINY-Breast11 clinical trial results. Read more: https://bit.ly/4uU4KsT

Join us on Jun. 9, 2026, at 2 PM CT for a webinar featuring Dr. Ana Garrido-Castro from Dana-Farber Cancer Institute as she speaks on the current treatments and recent research for metastatic triple negative breast cancer. Register today: https://bit.ly/4nJEeA4

A new national poll shows 90% of voters support proposals that would eliminate out-of-pocket costs for imaging and additional testing for people who require it.

The FDA has approved Veppanu (vepdegestrant), a first-of-its-kind daily oral pill that completely destroys treatment-resistant estrogen receptors in ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Learn more: https://bit.ly/3PLkP5e

Join us in our @ascocancer.bsky.social partnered panel: “Empowering Voices: Confronting the Rising Incidence of Cancer in Young Adults" 📅 May 30 | 11 a.m. CT 📍Patient Advocacy Lounge Moderator: Krissa Smith, Ph.D. Panelists: Sue Friedman, DVM, @arosen380.bsky.social, Letícia Varella, MD

The WISDOM clinical trial is helping reshape the future of mammograms by offering women screening recommendations based on their unique risk, using factors like genetics, lifestyle and medical history. Learn more: https://bit.ly/4wIeo3J

Stand for H.E.R. - a Health Equity Revolution is our commitment to help create a world without inequities in the Black community. Visit komen.org/standforher to learn more.

How are you honoring mom this Mother's Day?

Clinical trials offer people facing breast cancer hope & a chance at longer, healthier lives. But these opportunities only matter if people can access them. Our mission staff explains how patient navigators play an essential role in guiding patients to the right ones: https://bit.ly/4dsQ6mq

The words we use matter. Your loved one facing MBC needs to feel heard, supported and cared for. We know it can be hard finding the right thing to say. Here are some suggestions from our Metastatic Breast Cancer Steering Committee.

Our Metastatic Breast Cancer Steering Committee is comprised solely of people living with MBC and seeks to ensure the unique needs of the MBC community are integrated across our programs and initiatives. Learn more about the committee and keep an eye on all upcoming events: https://bit.ly/4cqP3jg

What are clinical trials? Where can I find one? Why does research take so long to get to market? Join us for our first-ever Metastatic Breast Cancer Impact Series Livestream on YouTube on April 28 at 1 PM CT. Learn all about clinical trials from our own Kelsey Hampton, PhD. https://bit.ly/4to492b

A mammogram is not the only breast imaging test. Different screening tools can provide different information. Learn about screening mammography, ultrasound, MRI, and more in our latest Know More blog: https://bit.ly/48RkrIH

What actually happens during a mammogram? This "Under the Microscope" video explains the exam from start to finish in under 3 minutes.

FOFO, or the fear of finding out, keeps many people from opening their test results or getting screened, but avoiding this information can delay critical care. That’s why early detection and clear, trusted information can make a life-saving difference. Learn more: https://bit.ly/3PNUbIN

Screening tests are used to find breast cancer early. Talk with your doctor about your risk of breast cancer and the screening plan that's best for you.

Closing out Triple Negative Breast Cancer (TNBC) Awareness Month is a NEW Breast Cancer Breakthroughs! Hear from experts as they discuss treatment of metastatic TNBC. Watch here: https://bit.ly/3PJbVVt

A new Komen-funded study from grantee Dr. Pedram Razavi showed how some metastatic HR+ breast cancers with BRCA mutations become resistant to CDK4/6 inhibitors. Findings suggest that starting PARP inhibitors earlier may delay this resistance & improve outcomes. https://bit.ly/4sEbCti

If you’ve been diagnosed with breast cancer, talk with your doctor about gene mutations and what testing may be right for you. https://bit.ly/47aEm4w

Hurry you don't want to miss this! Reba McEntire is hitting the stage with Trisha Yearwood and friends on March 22 at the Grand Ole Opry! Join us at Band As One Nashville for a night of performances in the fight against breast cancer. Get your tickets today: https://bit.ly/4owKjPA